Fast Market Research

"PharmaPoint: HIV - Japan Drug Forecast and Market Analysis to 2022" Published

New Pharmaceuticals market report from GlobalData: "PharmaPoint: HIV - Japan Drug Forecast and Market Analysis to 2022"

 

Boston, MA -- (SBWIRE) -- 04/29/2013 -- GlobalData has released its new Country report, "PharmaPoint: HIV - Japan Drug Forecast and Market Analysis to 2022". Human Immunodeficiency Virus (HIV), the causative agent of AIDS, has claimed millions of lives since its emergence. However, the advent of antiretroviral therapy (ART) has transformed the face of HIV/AIDS from a deadly disease to a manageable chronic condition for most infected individuals. Antiretroviral treatment not only reduces the viral load and reconstitutes immune function, but also decreases infection incidence rates by limiting viral transmission. The treatment algorithm in HIV has characteristically involved multiple drug regimens designed to tackle the virus on different levels. In the recent past, simplified dosing regimens through the emergence of single tablet regimens (STRs) or fixed dose combination (FDC) therapies have become increasingly popular amongst physicians and patients alike by increasing clinical efficacy thresholds and enabling patient compliance.

View Full Report Details and Table of Contents

This can be explained by the low prevalence and incidence rates of HIV in Japan. The Japanese market is different from the other major markets in that STR use has not yet been introduced. For example, Atripla, which is the market leader in the US and Europe, is not currently licensed in Japan. However, the first integrase-based STR, Gilead's Stribild, which was approved by the FDA in August 2012, might be launched in Japan by the end of 2013 or at the beginning of 2014. Japan Tobacco, through its research alliance with Gilead, filed for market approval of elvitegravir in December 2012 with the Japanese Ministry of Health, Labour and Welfare. GlobalData believes that ViiV will adopt a similar approach to launch the novel INI-based inhibitor dolutegravir and 572-Trii into the Japanese market.

Scope

- Overview of Japan including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in Japan including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in Japan from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting Japan HIV market.

Reasons to Get This Report

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for HIV
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012-2022 in Japan

About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- PharmaPoint: HIV - Brazil Drug Forecast and Market Analysis to 2022
- PharmaPoint: HIV - United Kingdom Drug Forecast and Market Analysis to 2022
- PharmaPoint: HIV - Germany Drug Forecast and Market Analysis to 2022
- PharmaPoint: HIV - Spain Drug Forecast and Market Analysis to 2022
- PharmaPoint: HIV - US Drug Forecast and Market Analysis to 2022
- PharmaPoint: HIV - France Drug Forecast and Market Analysis to 2022
- PharmaPoint: Prostate Cancer - United States Drug Forecast and Market Analysis to 2022
- PharmaPoint: Prostate Cancer - Italy Drug Forecast and Market Analysis to 2022
- PharmaPoint: Prostate Cancer - France Drug Forecast and Market Analysis to 2022
- PharmaPoint: Prostate Cancer - United Kingdom Drug Forecast and Market Analysis to 2022